13:30–16:45 Pre–Meeting workshops  
See program at page 9

17:00–18:00 Satellite Symposia  
See program at page 12

18:15 Welcome from LEPTIS MAGNA ROOM  
the World Scleroderma Foundation

18:30 Welcome from the Patron LEPTIS MAGNA ROOM  
of the World Scleroderma Foundation  
The impact of scleroderma on a creative genius  
A. Klee (CH)

18:45–19.00 Welcome from LEPTIS MAGNA ROOM  
the Patients’ Representative  
The Patients’ Perspective  
A Kennedy (IRL), President of FESCA

19:00-19:40 Opening Lectures LEPTIS MAGNA ROOM  
Two-years in Review-What’s new since  
Madrid: the Cutting Edge  
Chairpersons: C Black (UK), F Wollheim (S)

19:00 The clinical overview  
M Matucci-Cerinic (I)

19:20 The basic and translational I overview  
J Varga (USA)

19:40 Rome Video

20:00 Light welcome cocktail
FRIDAY, FEBRUARY 7

08:00–09:20 Session 1
LEPTIS MAGNA ROOM
Management and assessment of newly diagnosed SSc
Chairpersons: J van Laar (UK), N Damjanov (SR)

08:00 What to do for a patient with newly diagnosed SSc
- How to assess a patient with new onset of possible systemic sclerosis
- What are the standard of care tests in early SSc patient
- What are the baseline factors of poor prognosis in very early and early SSc
P Clements (USA)

Chairpersons: F Van den Hoogen (NL), S Johnsson (CAN)

08:20 NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE
O Distler et al (CH)

08:30 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE.
J Pope et al (CAN)

08:40 PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR–EULAR SYSTEMIC SCLEROSIS (SSc) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSc
P Carreira et al (E)

08:50 EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS
T Tay et al (AUS)

09:00 PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING
R Dobrota et al (R)

09:10 SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT
M Whitfield et al (USA)

09:20–10:10 Session 2
LEPTIS MAGNA ROOM
Miscellaneous and differential diagnosis of SSc
Chairpersons: U Walker (CH), R Silver (USA)

09:20 How to differentiate SSc from scleroderma-like disorder?
- Criteria for very early and early diagnosis of SSc
- Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis
A Tyndall (CH)

09:40 GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS
M Elhai et al (F)

09:50 EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META–ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY
S Johnson et al (CAN)

10:00 JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY
J Avouac et al (F)

10:10–10:30 COFFEE BREAK
10:30–11:00 Session 3  
**LEPTIS MAGNA ROOM**

**The great debate**  
Chairpersons: R Giacomelli (I), B Maurer (CH)  
The place of Corticosteroids in SSc  
T Medsger (USA), J Seibold (USA)

11:00–12:00 Poster tours  
**Clinical**  
Poster tour 1: Raynaud & Ulcers - V Riccieri (I)  
PS01 to PS06  
Poster tour 2: Raynaud & Ulcers - E Rosato (I)  
PS07 to PS12  
Poster tour 3: Pulmonary / Interstitial Lung Disease - I H Tarner (D)  
PS13 to PS19  
Poster tour 4: Pulmonary Arterial Hypertension - D Launay (F)  
PS20 to PS27  
Poster tour 5: Cardiac - A Vacca (I)  
PS28 to PS34  
Poster tour 6: Outcomes, quality of life, psychological & social - P Carreira (E)  
PS35 to PS41  
Poster tour 7: Imaging - F Cozzi (I)  
PS42 to PS48  
Poster tour 8: Therapy/Miscellaneous - A Sulli (I)  
PS49 to PS55  
Poster tour 9: Musculoskeletal system & rehabilitation - P Ostojic (SRB)  
PS56 to PS61  
Poster tour 10: Upper and Lower Gastrointestinal/nutrition - T Minier (H)  
PS62 to PS68  
Poster tour 11: Pregnancy & sexual problems - L Saketkoo (USA)  
PS69 to PS73  
Poster tour 12: Therapy - S Bellando-Radone (I)  
PS74 to PS82  

**Basic**  
Poster tour 13: Pathogenesis - M Manetti (I)  
PS83 to PS94  
Poster tour 14: Pathogenesis - GL Moroncini (I)  
PS95 to PS102  
Poster tour 15: Pathogenesis - S Assassi (USA)  
PS103 to PS111

12:00–13:30 Satellite Symposia  
See program at page 11

13:30–14:30 Working lunch  
**LEVEL – 2**

14:30–15:30 Satellite Symposia  
See program at page 11

15:30–16:40 Concurrent Sessions  
**LEPTIS MAGNA ROOM**  
**Concurrent Session 4**  
An integrated approach to gastro–intestinal involvement  
Chairpersons: A Herrick (UK), T Frech (USA)

15:30 GI: How to evaluate, diagnose and treat upper and lower GI involvement - U Mueller–Ladner (D)
15:50  New therapeutic approaches  
C Murray (UK)

16:10  MORTALITY, RECURRENCE, AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED ACUTE INTESTINAL PSEUDO–OBSTRUCTION  
C Derk et al (USA)

16:20  PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE–CONTROL STUDY  
E Ghrenassia et al (F)

15:30–16:40 Concurrent Session 5  
MASSALIA ROOM  
Links to inflammation, immunity and vascular disease  
Chairpersons: J Distler (D), D Abraham (UK)

15:30  Immunological mechanisms of fibrosis  
T Wynn (USA)

15:50  PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO  
V Liakouli et al (I)

16:00  SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING  
I Kajihara et al (JPN)

16:10  IL 6 TRANS –SIGNALLING AND CCL2 CO –REGULATE FIBROBLAST DEPENDENT TRANS –ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA  
R Alade et al (UK)

16:20  THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS  
G Salazar et al (USA)

16:30  THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELIUM: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION  
B Kahaleh et al (USA)

16:40–16:55 COFFEE BREAK

16:55–18:15 Concurrent Sessions

16:55–17:25 Concurrent Session 6  
LEPTIS MAGNA ROOM  
Biologics and novel therapies in SSc  
Chairpersons: R Simms (USA), C Beyer (D)

16:55  Use of biologics in SSc–indications and future perspective  
- An update on the use of biologics in SSc  
- Benefit/risk ratio of the main molecules  
- Upcoming trials  
Y Allanore (F)

17.25–17:55 Concurrent Session 7  
LEPTIS MAGNA ROOM  
Treatment and DMARDS in SSc  
Chairpersons: P Sampaio Barros (BRA), M Kuwana (JPN)

17:25  How to treat rapidly progressive SSc  
C Denton (UK)

16:55–18:15 Concurrent Session 8  
MASSALIA ROOM  
Mechanism of fibrosis  
Chairpersons: A Gabrielli (I), R Lafyatis (USA)

16:55  Biomechanical Signaling of Myofibroblast Activation  
V Thannickal (USA)

17:15  SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR–BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS  
B Sumova et al (D)
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:25</td>
<td>Investigating the role of myocardin related transcription factor (MRTF) in systemic sclerosis</td>
<td>X Shiwen et al (UK)</td>
</tr>
<tr>
<td>17:35</td>
<td>Ephrin B2 is overexpressed in human scleroderma skin and mediates fibroblast to myofibroblast differentiation, and induces fibrosis in mice</td>
<td>M Kapoor et al (CAN)</td>
</tr>
<tr>
<td>17:45</td>
<td>Experimental renal injury in a TGFbeta dependent mouse model of scleroderma</td>
<td>E Derrett-Smith et al (UK)</td>
</tr>
<tr>
<td>17:55</td>
<td>Direct thrombin inhibitor dabigatran etexilate protects alveolar epithelial cells from apoptosis in a bleomycin model of scleroderma-associated interstitial lung disease</td>
<td>G Bogatkevich et al (USA)</td>
</tr>
<tr>
<td>18:05</td>
<td>Stimulation of the soluble guanylate cyclase (SGC) inhibits dermal fibrosis by blocking non-canonical TGF-beta-signaling</td>
<td>C Beyer et al (D)</td>
</tr>
</tbody>
</table>

**SATURDAY, FEBRUARY 8**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 9</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–09:00</td>
<td>Meet the Professors session</td>
<td>Cesarea Room</td>
</tr>
<tr>
<td></td>
<td>Approach to SSc-Related Cardiac Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L Czirjak (H) &amp; Y Allanore (F)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Approach to Kidney Management</td>
<td>Efeso Room</td>
</tr>
<tr>
<td></td>
<td>L Guillevin (F) &amp; C Denton (UK)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 10</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:40</td>
<td>Cardiovascular involvement</td>
<td>Leptis Magna Room</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: M Inanc (TR), A Vacca (I)</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Conduction and Rhythm defects in scleroderma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C Meune (F)</td>
<td></td>
</tr>
<tr>
<td>09:20</td>
<td>Improvement of digital ulcerative disease in patients with systemic sclerosis is associated with better functional prognosis</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Prediction of cardiac and vascular events in systemic sclerosis: Input from Endothelin-1 Type A Receptor Antibodies</td>
<td></td>
</tr>
<tr>
<td>09:40–10:30</td>
<td>Interstitial Lung Disease</td>
<td>Leptis Magna Room</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: B Kahaleh (USA), O Kowal Bielecka (Pl)</td>
<td></td>
</tr>
<tr>
<td>09:40</td>
<td>SSc–ILD: Who to treat and how to treat?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Discuss natural history and disease progression in ILD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- How to identify patients who require immuno suppressive therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Efficient drugs and predictors of response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Khanna (USA)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>10:00</td>
<td>PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)</td>
<td>LEPTIS MAGNA ROOM</td>
</tr>
<tr>
<td>10:10</td>
<td>SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW.</td>
<td>LEPTIS MAGNA ROOM</td>
</tr>
<tr>
<td>10:20</td>
<td>GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS: AN IMMUNOCHIP STUDY</td>
<td>LEPTIS MAGNA ROOM</td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>COFFEE BREAK</td>
<td>LEPTIS MAGNA ROOM</td>
</tr>
</tbody>
</table>
| 10:45-11:55 | Session 12  
**Pulmonary Arterial Hypertension**  
Chairpersons: V Steen (USA), E Hachulla (F) | LEPTIS MAGNA ROOM             |                                                                                         |
| 10:45 | PAH: How to make the right diagnosis at the right time  
- Risk factors and predictors of PAH  
- Criteria guiding the clinician to refer the patient for catheterisation  
- How to interpret catheterisation  
Chairpersons: M Hinchcliff (USA), L Chung (USA) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:00 | CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY  
Chairpersons: L Saketkoo et al (USA) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:15 | RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION  
Chairpersons: D Khanna et al (USA) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:25 | A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
Y J Hao et al (AUS) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:35 | CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL HYPERTENSION BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY PULMONARY HYPERTENSION  
R Domsic et al (USA) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:45 | PROGNOSTIC VALUE OF NT–PROBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY HYPERTENSION  
M Antivalle et al (I) | LEPTIS MAGNA ROOM             |                                                                                         |
| 11:55-12:10 | Special Lecture  
Chairpersons: F Del Galdo (UK), G Riemekasten (D) | LEPTIS MAGNA ROOM             | DeSScipher, a jump in the future!  
U Mueller-Ladner (D) |
| 12:10-12:30 | Summary of the congress  
Chairperson: L Guillevin (F) | LEPTIS MAGNA ROOM             | Highlights of the World Scleroderma Congress, 2014  
D Furst (USA) |
| 12:30-13:00 | Closing Ceremony | LEPTIS MAGNA ROOM             |                                                                                         |